Prosonix is developing a portfolio of engineered pharmaceutical mono and combination inhalation therapy products that offer distinct and high value advantages to patients. 

With proven delivery across a range of both dry powder inhalers (DPI) and metered dose inhalers (MDI), Prosonix has already demonstrated in-vitro bioequivalence for a range of now directly substitutable generic products and "best-in-class" delivery for several novel therapeutic targets.

Our innovative pipeline addresses the large and fast-growing market sectors of asthma and COPD, and combines our own leading particle engineering developments on a range currently marketed products with our clients' clinical development programmes.

Niche opportunities also exist for several novel orally and parentally delivered products, in particular those exhibiting poor aqueous solubility where particle size and morphology control is a very important consideration.

Prosonix welcomes enquiries from all parties interested in licensing and co-development opportunities.

Please contact David Hipkiss CEO or Christian Jones BDM or Contact us

Please click for In-house development pipeline

Please click for Partnered development pipeline